SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
AKTS reported Third quarter ended September 30, 2026 results. The stock moved -4.5% on the print.
AKTSearnings

Earnings reactions, page 3

Aktis Oncology, Inc. (AKTS) Q3 FY2026 earnings

November 12, 2026 · SharpeIQ Research Desk

Reported results

  • Collaboration revenue was $3.9 million for the quarter ended September 30, 2026.
  • Research and development expenses were $32.1 million for the quarter ended September 30, 2026.
  • General and administrative expenses were $6.5 million for the quarter ended September 30, 2026.
  • Net loss was $29.9 million for the quarter ended September 30, 2026.
  • Cash, cash equivalents, and marketable securities were $492.9 million as of September 30, 2026.

Guidance

  • Expect preliminary data for AKY-1189 in the first quarter of 2027.
  • Expect preliminary data for AKY-2519 in 2027.
  • Expect to expand drug supply to include in-house GMP facility in the first half of 2027.
  • Cash, cash equivalents, and marketable securities as of September 30, 2026, are expected to fund the Company’s operating plan into 2029.

Price and volatility reaction

The stock moved -4.5% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release17.042026-11-11
Close after release16.282026-11-12
Realised move-4.5%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →